Cataflam is commonly used to help with symptoms related to physical discomfort and inflammatory states. The medication is relevant when supportive symptom management is appropriate, offering supportive therapeutic benefit.

The medication is commonly used to help with several clusters of symptoms across different therapeutic contexts. These indications include symptomatic support for primary dysmenorrhea (menstrual cramps), migraine attacks, and is considered relevant for easing the signs and symptoms of osteoarthritis and rheumatoid arthritis. It is also commonly used in scenarios where short-term symptomatic assistance is needed following post-traumatic injuries like sprains and strains, or after minor procedures.

“The medication is commonly applied in clinical settings that involve acute or disruptive symptom patterns.”

---

Quick Fact: Management for Pain, Swelling, and Stiffness

Cataflam generally contributes to easing the overall symptom load during periods of heightened symptoms. It is applied when appropriate and is considered relevant for easing symptoms related to pain, swelling, and stiffness. It may help patients cope more steadily with symptom fluctuations when chronic conditions become more noticeable. This supportive action may help maintain a sense of stability during episodes of acute discomfort.

Regulatory References

1. NIH MedlinePlus overview on Diclofenac

The use of Cataflam (diclofenac potassium) is strictly governed by regulatory eligibility rules based on a patient’s health status and age. The drug is generally intended for adults and adolescents 14 years of age and older, but use in children under this age is generally not recommended or established for the immediate-release tablet form.

Contraindicated Populations

The medicine must not be used by patients who fall into the following regulatory-defined categories:

• Hypersensitivity: Those with a known history of severe allergic reactions (e.g., asthma, urticaria) to diclofenac, aspirin, or any other NSAID.
• Severe Organ Failure: Patients with severe hepatic failure or severe renal failure (GFR <15 mL/min/1.73m^2)
• Gastrointestinal Risk: Individuals with active gastrointestinal ulceration, bleeding, or perforation.
• Cardiovascular: Patients with established congestive heart failure (NYHA Class II-IV) or who are in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.
• Pregnancy: Use is absolutely contraindicated during the last trimester of pregnancy (at or after 30 weeks gestation).

Conditional and Restricted Use

Use requires caution and is often subject to strict limitations in older adults and patients with mild to moderate hepatic or renal impairment. Furthermore, use is not recommended in women who are breastfeeding.

The official regulatory profile for Cataflam (diclofenac potassium) documents several clinically significant interactions, classified by their pharmacokinetic or pharmacodynamic outcomes. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin is generally restricted due to the heightened, additive risk of serious gastrointestinal adverse events. High-risk combinations also include oral anticoagulants, antiplatelet agents, and Selective Serotonin Reuptake Inhibitors (SSRIs), which increase the documented potential for hemorrhage.

The medicine's exposure is sensitive to the CYP2C9 enzyme system. Potent CYP2C9 inhibitors, such as voriconazole, increase diclofenac plasma concentrations, while inducers, like rifampin, may decrease them. Cataflam is documented to reduce the renal clearance of both Lithium and Methotrexate, which results in increased plasma concentrations of these co-administered medicines.

Pharmacodynamic interactions include the potential to decrease the antihypertensive effect of ACE Inhibitors and ARBs, and lessen the natriuretic effect of diuretics. Co-administration with Cyclosporine or Tacrolimus increases the documented risk of nephrotoxicity. For agents such as Cholestyramine, the official labeling requires a separation of administration by four to six hours to prevent reduced absorption. Interaction severity is noted as being of greater clinical significance in elderly patients and those with pre-existing renal impairment.

The pharmacological effect of Cataflam (Diclofenac potassium) is governed by a precise engagement with core biological pathways, leading to the engagement with pathways that control specific physiological responses. Its mechanism operates across three principal domains.

Molecular Blockade of Cyclooxygenase (COX) Enzymes

This domain focuses on the primary biological targets: the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. The drug functionally blocks these enzyme active sites, immediately suppressing the conversion of arachidonic acid into pro-inflammatory mediators like prostaglandins. This action is the foundational molecular step leading to subsequent physiological effects.

Modulation of Peripheral Inflammatory Signaling

By substantially reducing prostaglandin synthesis at the site of tissue irritation, the drug's mechanism intervenes in the inflammatory cascade. This results in the reduction of peripheral nociceptive signaling and reduces the localized vascular responses, such as vasodilation and increased permeability, directly interfering with the concentration of chemical mediator activity on nerve fibers and blood vessels.

Central Thermoregulatory Adjustment

A distinct mechanistic action occurs centrally within the hypothalamus. The same COX inhibition mechanism limits the production of PGE2 in the brain, a key molecule responsible for elevating the body’s thermal set-point. This allows for the lowering of the hypothalamic temperature set-point, aligning the overall effect profile with the resulting systemic physiological effects.

Official Administration Guidelines

Cataflam (diclofenac potassium immediate-release tablets) is administered strictly via the oral route. Standard use protocols center on two core principles: using the lowest effective dose and limiting treatment to the shortest duration possible.

---

Dosing and Scheduling

Administration is defined by condition-specific numerical dose ranges and must be taken in divided doses multiple times per day (e.g., two to four times daily), as opposed to a single daily dose. The total daily intake typically ranges from 100 mg to 200 mg, depending on the specified condition, with strict adherence to the maximum daily limit. For example, the total daily dosage for conditions such as osteoarthritis is generally 150 mg or less, while some conditions permit up to 200 mg.

---

Administration Specifics

• Intake: The tablets must be swallowed whole with liquid. They should not be crushed or chewed.
• Food Relationship: The medication may be taken with or without food. Taking it with food may result in a delay in the onset of action, but it does not significantly impact the overall extent of absorption.
• Concomitant Use: General guidelines advise against the concurrent use of Cataflam with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

---

Population-Specific Rules

• Older Adults: Administration requires caution, and the lowest effective dose should be used for the briefest duration possible.
• Pediatrics: The drug is not generally recommended for use in children under 14 years of age for systemic anti-inflammatory indications.

Research Evidence / Overview of Studies for Cataflam

---

Evidence for Use in Acute Pain States

Research exploring the study landscape for Cataflam (diclofenac potassium) for acute pain includes short-term, randomized controlled trials (RCTs) and single-dose studies. These studies were used in research exploring how symptoms change over time and were conducted during periods of increased symptom activity, such as following minor procedures or in acute post-traumatic injury. The research examined outcomes related to physical discomfort in studies that involved short observation intervals, typically ranging from a single dose up to a few days. Findings describe patterns observed in these studies, reporting measured changes in pain intensity between the compound and the comparison group. Long-term functional outcomes following post-traumatic events appear not to be fully established by the existing evidence. Results apply only to the specific, generally healthy adult populations studied.

---

Evidence for Use in Primary Dysmenorrhea and Acute Migraine

The evidence for primary dysmenorrhea (menstrual cramps) was evaluated in specialized, double-blind, placebo-controlled crossover studies designed to assess fluctuating symptoms. Studies examined outcomes reflecting daily functioning during the acute symptomatic phase. For acute migraine attack, research examined temporary physiological imbalance. Trials evaluated the compound in settings associated with acute episodes, and data show patterns related to the measurement of a pain-free state and the reporting of changes in associated symptoms. The evidence for both conditions was studied in the acute phase. Follow-up durations were limited, and research is restricted to the treatment of a single attack, providing no insight into long-term management.

---

Evidence for Use in Chronic Inflammatory Conditions and Special Populations

Cataflam was evaluated in conditions characterized by fluctuating symptoms, such as osteoarthritis and rheumatoid arthritis. Research explored short-term symptom changes using randomized controlled trials, monitoring outcomes linked to inflammatory states, including joint pain and stiffness. The evidence for use in chronic conditions explores limited follow-up durations, with most treatment periods lasting only up to 30 days. Research has also evaluated the compound in specific populations, such as pediatric subjects, primarily through pharmacokinetic (PK) studies that focus on how the medicine is processed by the body, rather than large-scale efficacy trials. Data for certain groups, such as older adults, often remain insufficient within the primary efficacy trials.

Key Studies & References Diclofenac - MedlinePlus Drug Information (NIH)

Common questions about Cataflam (FAQ)

Q: How quickly does Cataflam start working after taking it?

A: According to official product information, measurable levels of the active ingredient may be observed in the blood within 10 minutes of administration. In individuals who are fasting, the highest concentration in the bloodstream is typically reached in approximately one hour. This formulation is designed to provide a rapid onset of action for acute pain states.

Q: How long does the pain relief from Cataflam usually last?

A: Pharmacokinetic data from regulatory documents indicate that the time it takes for half of the unchanged active ingredient to be eliminated from the body, known as the terminal half-life, is approximately 1.9 hours.

Q: What happens if I take Cataflam and then drink alcohol?

A: Official regulatory warnings state that consuming alcohol while using Cataflam may increase the documented risk of serious gastrointestinal adverse events, such as bleeding in the stomach or intestines. The official information notes the importance of being aware of this potential for increased risk when considering alcohol use.

Q: Does Cataflam interfere with blood thinning medication?

A: Yes, official regulatory texts note that co-administration with certain blood thinning medicines, specifically oral anticoagulants and antiplatelet agents, can increase the documented potential for hemorrhage (bleeding). This is considered a clinically significant interaction described in the product labeling.

Q: Does Cataflam affect blood sugar levels?

A: Although clinical studies show that the drug can be used with oral antidiabetic medicines, regulatory documents include isolated reports of both lower (hypoglycemic) and higher (hyperglycemic) blood sugar effects. Monitoring of blood sugar levels may be considered in patients using Cataflam concurrently with antidiabetic treatments.

Q: What should I do if I forget to take a dose of Cataflam?

A: If a dose is missed, patient guidance generally indicates taking it as soon as you remember. However, if it is almost time for the next scheduled dose, patient guidance generally indicates skipping the missed dose and returning to the regular dosing schedule. The guidance states that a double dose should not be taken to compensate for a missed one.

Q: Are there any specific foods or drinks to avoid when using Cataflam?

A: General regulatory guidance advises against consuming alcohol due to the increased risk of gastrointestinal bleeding. However, there are no common warnings against most other specific foods or drinks, and the medication may be taken with or without food.

Q: What is the main difference between Cataflam and regular diclofenac?

A: Cataflam is a specific formulation that uses diclofenac potassium in an immediate-release tablet. This formulation is designed to promote quicker dissolution and absorption in the body for a faster onset of action, setting it apart from other formulations that often use the diclofenac sodium salt or delayed-release technology.

Q: Can Cataflam be used for tooth pain or dental procedures?

A: Official information indicates that the drug is approved for the relief of mild to moderate pain. Acute pain states such as dental pain are commonly included within the scope of this general indication and evaluated in studies of diclofenac.

Q: Does Cataflam treat headaches or migraines?

A: The compound is indicated for the relief of mild to moderate pain, which may encompass some types of headaches. Additionally, official regulatory documents note that the drug has been evaluated in research for the treatment of acute migraine attacks.

Q: Is there a risk of heart problems associated with Cataflam use?

A: Yes, regulatory warnings state that use may increase the risk of serious cardiovascular thrombotic events, which include myocardial infarction (heart attack) and stroke. The medicine is also contraindicated in patients with established congestive heart failure (NYHA Class II-IV).

Q: Is Cataflam used for fever reduction?

A: Yes, regulatory descriptions of the drug characterize it by its triple physiological actions, including the antipyretic (fever reducing) effect. This means the drug's mechanism operates to help normalize an elevated body temperature.

Q: Does Cataflam make you gain weight?

A: Official warnings note that fluid retention and swelling (edema) have been observed with use. Rapid or unusual weight gain is listed as a potential sign of a serious adverse event that warrants monitoring.

Q: Is there a link between Cataflam and liver damage?

A: Yes, regulatory warnings state that the medication may cause liver damage (hepatotoxicity). This includes rare cases of severe liver failure and is a risk factor that requires the monitoring of liver function during treatment.

Q: What are the signs of an allergic reaction to Cataflam?

A: Signs of a serious allergic reaction may include difficulty breathing, swelling of the face, tongue, or throat, or the presence of hives, rash, blistering, or peeling of the skin. These signs warrant immediate medical attention.

Q: Is it okay to take Cataflam if I have asthma?

A: Cataflam is strictly contraindicated in patients with a history of allergic-type reactions (such as asthma or hives) to aspirin or other NSAIDs. For patients with preexisting asthma that is not related to NSAID sensitivity, regulatory guidance states that use should be approached with caution and signs of asthma should be monitored.

Q: Are there long-term side effects from using Cataflam?

A: Official guidance recommends using Cataflam only for short-term treatment. If the medicine is used for a prolonged period, monitoring of blood count and liver function is described in official documents due to the potential for serious adverse events that increase with duration of use.

Q: Why is the active ingredient in Cataflam potassium instead of sodium?

A: The use of the potassium salt formulation is intended to promote quicker dissolution and absorption in the body compared to the sodium salt. This rapid absorption is a key feature of the Cataflam formulation, particularly for the treatment of acute pain states.

Q: Is Cataflam available over the counter in some countries?

A: While the specific 50 mg Cataflam tablet is generally categorized as a prescription-only drug, diclofenac potassium is available in lower doses (such as 12.5 mg) as an over-the-counter medicine in some international regulatory regions.

Q: Does Cataflam have a risk of causing stomach bleeding?

A: Yes, the regulatory warnings state that Cataflam increases the risk of serious gastrointestinal adverse events. These events can include bleeding, ulceration, and perforation of the stomach or intestines, and this risk can occur without warning symptoms.

Q: Does Cataflam interact with high blood pressure medicines?

A: Yes, regulatory documents indicate that Cataflam can interact with certain high blood pressure medicines. Specifically, it may potentially decrease the antihypertensive effect of medicines such as ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics.

How to Store and Dispose of Cataflam?

Official regulatory guidelines strictly define the conditions necessary for storing and disposing of Cataflam (diclofenac potassium) to maintain its stability and ensure public safety.

Storage Requirements

Cataflam must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The container should be kept tightly closed to protect the medicine. As with all medications, it must be stored safely, out of the reach of children.

Disposal Instructions

To dispose of unused or expired Cataflam, use a local drug take-back program if one is available. If a take-back option is not available, the medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag or container, and thrown into the household trash. Do not flush this medicine down a toilet or pour it down a drain.